DIA中国第二届药物研究创新会议

The2ndDIAChinaDrugDiscoveryInnovationConference2016年10月24-26日|苏州希尔顿逸林酒店|中国October24-26,2016|DoubleTreebyHiltonHotelSuzhou,China2016年10月24日——会前专题研讨会和开幕大会2016年10月25-26日——会议和展览24October,2016-PreconferenceWorkshops&OpeningPlenary25-26October,2016-Conference&ExhibitionFinalProgram大会手册7大会主席/PROGRAMCHAIR大会副主席/PROGRAMVICECHAIR大会指导委员会STEERINGCOMMITTEE组委会成员PROGRAMCOMMITTEE鲁先平博士深圳微芯生物科技有限公司总裁兼首席科学官牟骅博士先声药业集团首席科学官研发总裁XianpingLU,PhDCEO&ChiefScientificOfficer,ChipscreenBiosciences,Ltd.
Shenzhen,ChinaHuaMU,MD,PhDChiefScientificOfficer,R&DPresident,SimcerePharmaceuticalGroup陈力博士华领医药技术(上海)有限公司董事长,总经理纪晓辉博士罗氏全球合作部,副总裁亚洲及新兴市场总负责人申华琼博士杨森制药中国研发科学事务部副总裁,临床研发负责人王英博士葛兰素史克上海研发中心药物安全评价部负责人LiCHEN,PhDCEO,HuaMedicine(Shanghai)Ltd.
DarrenJI,MD,PhD,MBAVicePresident,GlobalHeadAsiaandEmergingMarketsPartneringF.
Hoffmann-LaRocheLTD.
JoanSHEN,MD,PhDVicePresident,DevelopmentHead,ChinaR&DandScientificAffairs,JanssenCharlesY.
WANG,PhD,DABTDirectorandHeadofSafety,Assessment,GSKR&DShanghai邬征博士上海爱科百发生物医药技术有限公司,首席执行官谢雨礼博士上海药明康德新药开发有限公司CMC办公室主任闫小军工商管理硕士百济神州高级副总裁及药政事务部首席总监张志民博士,工商管理硕士乐土投资集团跨境投资董事总经理JimWU,PhDCEO,ArkBiosciencesInc.
YuliXIE,PhDDirectorofCMCofficeWuXiAppTecWendyYAN,MD,MBASeniorVicePresident,HeadofRegulatoryAffairsBeiGene(Beijing)Co.
,Ltd.
JimmyZHANG,PhD,MBAManagingDirector,Cross-borderInvestment,CLInvestmentGroup仲倞博士赛诺菲高级总监亚洲肿瘤研究负责人朱立红工商管理硕士DIA中国区董事总经理LiangSCHWEIZER,PhDSeniorDirectorHeadofAsianCancerResearch,SanofiCarolZHU,MBASeniorVicePresidentandManagingDirectorDIAGreaterChina27MONDAY,OCTOBER24,2016|CONFERENCEDAY107:30-17:301stFloorRegistrationOpen08:30-12:006thFloorFunctionRoom4Pre-conferenceWorkshop:NovelTechnologyApplicationsforDrugDiscovery13:30-17:006thFloorDoubleTreeGrandBallroomOpeningPlenary+SpecialForum15:30-16:006thFloor,FoyerRefreshmentBreak17:00-19:006thFloor,DoubleTreeGrandBallroom&FoyerWelcomeReceptionTUESDAY,OCTOBER25,2016|CONFERENCEDAY207:30-17:301stFloorRegistrationOpen08:30-10:006thFloorDoubleTreeGrandBallroom1Session101TargetSelection6thFloorDoubleTreeGrandBallroom2Session301EfficacyandDMPKofDrugCandidate10:00-10:306thFloor,FoyerRefreshmentBreak10:30-12:006thFloorDoubleTreeGrandBallroom1Session102TargetValidation6thFloorDoubleTreeGrandBallroom2Session302NonclinicalSafetyEvaluationandCMCtoSupportFTIHandPoCTrials12:00-13:305thFloorBuffetLunch13:30-15:006thFloorDoubleTreeGrandBallroom1Session201MedicinalChemistryinLeadIdentification/Optimization6thFloorDoubleTreeGrandBallroom2Session401INDManagementandCommunicationwithHealthAuthorities–Chinavs.
US6thFloorDoubleTreeGrandBallroom3Session701TargetandConceptValidationofAntibodyDrugs15:00-15:306thFloor,FoyerRefreshmentBreak15:30-17:006thFloorDoubleTreeGrandBallroom1Session202DiseasePharmacology,ADMEandEarlySafetyEvaluationtoSupportLeadCompoundNomination6thFloorDoubleTreeGrandBallroom2Session402TheBestPracticeforINDApplicationPreparation–Chinavs.
US17:00-19:002ndFloor,BeerSocietyVIPReception(VIPandSpeakerONLY)WEDNESDAY,OCTOBER26,2016|CONFERENCEDAY307:30-11:301stFloorRegistrationOpen08:30-10:006thFloorDoubleTreeGrandBallroom1Session601PartneringEarlytoAccelerateTranslationofScientificDiscoverytoClinicalBenefits6thFloorDoubleTreeGrandBallroom2Session501FromFirstinHuman(FIH)TrialtoClinicalProofofConcept(POC)10:00-10:306thFloor,FoyerRefreshmentBreak10:30-12:006thFloorDoubleTreeGrandBallroom1Session602Cross-borderBusinessDevelopment6thFloorDoubleTreeGrandBallroom2Session502AddressingChallengesfromCFDANewRequirementsonClinicalTrialConductandDataQuality12:00-14:006thFloorDoubleTreeGrandBallroom1LunchMeeting(InvitationtoMaster'sBalcony)14:30ShuttleBustoHongqiaoAirport,SuzhouRailwayStation,SuzhouNorthRailwayStationandSuzhouIndustrialParkRailwayStationQUICKGUIDETOTHEPROGRAM28MONDAY,24OCTOBER|PRCONFERENCEWORKSHOPSDrugdiscoverysciencehasbenefitedgreatlyfromtechnologyadvancement.
Withrapiddevelopmentofnoveltechnologies,drugdiscoveryenteredanexcitingeraforinnovation,translationalrelevance,processoptimizationetc.
Herewewouldliketointroducehowtheadvancementoftechnologycanbeappliedtodrugdiscoveryresearch.
Expertsfrombothacademicandindustrywillsharetheirexperiencesandspecificexampleshowtechnologyapplicationhasimpactedondrugdiscovery.
LEARNINGOBJECTIVEUnderstandhowtechnologycanbeappliedtodrugdiscoveryinnovationLearnspecificsofcellassaytechnologyandtranslationaltechnologyGaininsightoftechnologydevelopmentandfuturetrendsPROGRAMCOMMITTEELiangSCHWEIZER,PhDSeniorDirector,HeadofAsianCancerResearch,SanofiJeanQIU,PhDFounderandCTOofNexcelomBioscienceLLC.
Workshop(halfday)8:30-12:006F,FunctionRoom4NovelTechnologyApplicationsforDrugDiscoveryAGENDA8:30-10:00CellAssayTechnology3DMulticellularTumorSpheres:HowtoGetStartedScottCRIBBES,PhDDirectorofApplicationsandEmergingTechnologies,NexcelomBioscienceTheApplicationofHighThroughputCell-basedAssayinPrecisionMedicine.
JijunYUAN,PhDVice-GeneralManager/R&DHead,ShanghaiGenechemCo.
,Ltd.
10:30-12:00TranslationalTechnologyBiomimeticinVitroCellModelsandAssaysforCompoundRankinginDrugDiscoveryandDevelopment.
Dr.
HanryYUProfessorofPhysiology,NationalUniversityofSingapore(NUS)PDX,aTranslationalToolforOncologyDrugR&DDanyiWEN,PhDPresident&CEO,ShanghaiLIDEBiotechSAVETIMEANDTRAVELCOSTSwithIN-COMPANYTRAININGAllDIATrainingCoursecanbeheldonyourpremisesandtailoredtoyourneeds.
Getthebestvalueandtrainyourwholeteam!
29PlenarySessionsOpeningPlenaryMONDAY,24OCTOBER|13:30-17:00|6thFloor,DoubleTreeGrandBallroomSimultaneousTranslationWELCOMERECEPTIONMONDAY,24OCTOBER17:00-19:00|6F,DoubleTreeGrandBallroom&FoyerSPECIALFORUMCFDAReformandNationalNewDrugDevelopmentStrategy:theImpactonChinaDrugR&DandInnovationSPECIALFORUM:MODERATORHuaMU,MD,PhDChiefScientificOfficer,R&DPresident,SimcerePharmaceuticalGroupINVITEDPANELISTSRuyiHE,MDChiefScientist,CDE/CFDAQingLIDirector,DevelopmentCenterforMedicalScienceandTechnologyNationalHealthandFamilyPlanningCommissionofthePeople'sRepublicofChinaMichaelYU,PhDPresident&CEO,InnoventBiologics,Inc.
MinLI,PhDSVP&Head,NeuroscienceTherapeuticAreaUnitHead,R&DChinaGSKJunyongPANGCEOofBioBAYINTRODUCTIONANDACKNOWLEDGEMENTCarolZHU,MBASeniorVicePresidentandManagingDirector,DIAGreaterChinaWELCOMEADDRESSXianpingLU,PhDCEO&ChiefScientificOfficer,ChipscreenBiosciences,Ltd.
Shenzhen,China2ndDIAChinaDrugDiscoveryInnovationConferenceProgramChairWELCOMEADDRESSfromSuzhouIndustrialParkXiangWANGStandingMemberofCPCSuzhouMunicipalCommitteePartySecretaryofSIPWorkingCommitteeKEYNOTEADDRESSImprovingDrugEvaluationMethods,PromotingNewDrugDevelopmentinChinaRuyiHE,MDChiefScientist,CDE/CFDABiologicsContractManufacturing:AnInnovativeApproachtoChina'sEmergingBiotechnologyCommunityAxelSCHLEYER,PhD,MBAVPBusinessDevelopment&KeyAccountManagement,Americas&Asia/PacificBiopharmaceuticalsBoehringerIngelheimBiopharmaceuticals(China)Co.
Ltd.
30TUESDAY,25OCTOBERSpecialForumChinaLifeScienceParkInnovationForumSpecialForum|Tuesday,25October9:00-12:006F,DoubleTreeGrandBallroom3SESSIONCHAIRGuozhongRUIDirectorofChinaPharmaceuticalTechnologyTransferCenter(CPTTC),Secretary-GeneralandExecutiveViceChairmanofNationalBiomedicalParkIndustrialClusterCollaborativeInnovationAllianceDr.
JinWANGManagingDirectorofJianxinCapitalOsongBiomedicalClusterinKorea:theroleofKBIOHEALTHindevelopingasuccessfulpublic-privatepartnershipTaeGyuLEE,PhDPresident,OsongMedicalInnovationFoundation,NewdrugdevelopmentcenterOneDecade'sDevelopmentofbioBAYJunyongPANGPresidentofbioBAYInvitedGuestsforRoundtableDiscussionXianpingLU,PhDCEO&ChiefScientificOfficer,ChipscreenBiosciences,Ltd.
LiCHEN,PhDCEO,HuaMedicine(Shanghai)Ltd.
XuemingQIAN,PhDFounder,ChairmanandCEO,MabspaceBiosciencesTheme1TargetSelectionandValidationSession101|Tuesday,25October8:30-10:006F,DoubleTreeGrandBallroom1TARGETSELECTIONSESSIONCHAIRJimWU,PhDFounder&CEO,ArkBiosciencesTargetidentification,selectionandverificationarethefirststepsofdrugdiscoveryanddevelopmentprocess.
Thissessionwillhighlightkeytopicsandconsiderationofsuccessfultargetidentificationandselectioninrealsituationofdrugdiscoveryprojects.
Weinvitedthreebigpharmaveteransasspeakerstodiscusshowtheyperformeddrugtargetidentificationandselectionindifferentdiseaseareasusingdifferentapproaches.
HowDoWeStartDrugDiscoveryTargetIdentificationandValidationLiangSCHWEIZER,PhDSeniorDirector,HeadofAsianCancerResearch,SanofiHowtoIdentifyaDrugTarget:Qualification,Approach&ChallengeHongkangMEI,PhDHeadofComputationalandModelingSciences,R&DChina,GSKTheMindsetforTherapeuticareaandTargetSelectioninChinaInnovativeDrugDiscoveryYuliXIE,PhDDirector,PDSoperation/CMCoffice,WuXiAppTec(Shanghai)Co.
,LtdSession102|Tuesday,25October10:30-12:006F,DoubleTreeGrandBallroom1TARGETVALIDATIONSESSIONCHAIRLiangSCHWEIZER,PhDSeniorDirector,HeadofAsianCancerResearch,SanofiTargetidentification,selectionandverificationarethefirststepsofdrugdiscoveryanddevelopmentprocess.
Thissessionwillhighlightkeytopicsandconsiderationofsuccessfultargetvalidationinrealsituationofdrugdiscoveryprojects.
Expertsfromindustryveteranswilldiscusshowtheyperformeddrugtargetvalidationindifferentdiseaseaswellasprovidinginsightsfortheartoftargetvalidation.
CancerDrugDiscoveryinPrecisionMedicineandImmunotherapyEraQunshengJI,PhDVicePresident,BusinessUnitHead,Oncology,WuxiApptecTargetingAntibacterialResistanceandSuperbugsYongqianWU,PhDPresident&CEO,NanjingTransTheraBioscienceApproachingVariousMechanismsinDrugDiscovery:ValidationofMechanismsandTherapeuticMoleculesMinghanWANG,PhDCEO,PhanesTherapeuticsInc.
Theme2CompoundIdentification/OptimizationtoCompoundNominationSession201|Tuesday,25October13:30-15:006F,DoubleTreeGrandBallroom1MEDICINALCHEMISTRYINLEADIDENTIFICATION/OPTIMIZATIONSESSIONCHAIRHongSHEN,PhDHeadofMedicinalChemistry,RocheInnovationCenterShanghaiRecentlymultiplenovelsmallmolecularclinicalcandidateshaveemergedfrombothlocalChinesecompaniesandmulti-nationalpharmaceuticallabsbasedinChina.
InthissessiontwomedicinalchemistryexpertsfromShanghai-basedmulti-nationalpharmaceuticalcompanieswillsharetheirteameffortsinutilizingmedicinalchemistrytobringmoleculestoclinicaldevelopment,withafocusonleadidentificationandoptimization.
31TUESDAY,25OCTOBERDiscoveryofclinicalcandidateAZD3759QingbeiZENG,PhDPrincipalScientist,MedicinalChemistryAstraZenecaChinaDrugDiscoveryCenterMedicinalChemistryEnabledDrugDiscoveryatRocheInnovationCenterShanghaiHongSHEN,PhDHeadofMedicinalChemistry,RocheInnovationCenterShanghaiSession202|Tuesday,25October15:30-17:006F,DoubleTreeGrandBallroom1DISEASEPHARMACOLOGY,ADMEANDEARLYSAFETYEVALUATIONTOSUPPORTLEADCOMPOUNDNOMINATIONSESSIONCHAIRHenryLI,PhDVicePresident,TranslationalOncology,CrownBioscience,Inc.
Thissessionwilldiscusstwoimportantaspectsoftoday'sdrugdevelopment.
Inthisfirstpart,Dr.
Zhangdescribetherolesofdrugtransportersinsmallmoleculardrugdispositions,efficacyandtoxicity,anddiscusshowtheirunderstandingwouldhelptoguidesmallmoleculedrugdevelopment.
Inthesecondpart,Dr.
Liwillreviewavarietyofanimalmodelstosupportcurrentimmune-oncology(I/O)pharmacologyresearchbycomparingtheprosandconsofeachfordifferentapplications;andDr.
DongwillfocusonbiomarkerdiscoveryapplicationofspecifictypesofhumanizedI/OanimalmodelsTheRoleofTransportersinDrugDisposition,EfficacyandToxicityHongjianZHANG,PhDProfessor,MechanismsofDrugMetabolism&TransportSoochowUniversityAnimalModelingofImmune-oncologyTreatmentsHenryLI,PhDVicePresident,TranslationalOncology,CrownBioscience,Inc.
BiomarkerDiscoveryforImmune-OncologyTherapeuticswithHumanizedAnimalModeXinDONG,PhDCSOandR&DHeadNanjingGalaxyBiopharma,CO.
,LTD.
Theme3INDEnablingStudiesSession301|Tuesday,25October8:30-10:006F,DoubleTreeGrandBallroom2EFFICACYANDDMPKOFDRUGCANDIDATESESSIONCHAIRJasmineCUI,PhDPresident&CEO,BeijingInnoCarePharmaTechCo.
LtdTheselectedpre-clinicalcandidate(PCC)needstobeevaluatedinaseriesofinvivoefficacymodelsandDMPKexperimentspriortothesubmissionofIND.
It'scriticaltochooseappropriatemodelsfortheseevaluationstoachieveasuccessfulINDapproval.
Thissessionfocusesonthediscussiononhowtochoosethesemodelsandexperimentstoeconomicallyandscientificallymaximizetheresourcesforobtainingtheneededdatapackage.
Pre-clinicalEfficacyStudiesforEvaluationofDrugCandidateZuopengWANGSr.
DirectorofPM&Registration,BeijingInnoCarePharmaTechCo.
Ltd.
IntegratedDMPKEvaluationforDrugCandidateKellyDONG,PhDHeadofBioanalyticalScienceandToxicokinetics,GSKR&DShanghaiSession302|Tuesday,25October10:30-12:006F,DoubleTreeGrandBallroom2NONCLINICALSAFETYEVALUATIONANDCMCTOSUPPORTFTIHANDPOCTRAILSSESSIONCHAIRCharlesY.
WANG,PhD,DABTDirectorandHeadofSafety,Assessment,GSKR&DShanghaiThissessiondiscussesthenonclinicalsafetyevaluationandrelatedCMCworkfromcandidateselection(CS)toProofofConcept(PoC)basedontheregulatoryrequirement.
Atthisstage,usuallyupto13-weekrepeatdosingtoxicitystudiesinrodentandlargeanimals,genotoxicity,cardiovascularsafetypharmacologyandembryo-fetaldevelopment(SegII)studiesshouldbecompletedtosupportupto13weekrepeatdosingPoCtrialinhumansubjects.
TheearlyCMCinvestigationforNewChemicalEntity(NCE)includesAPIandformulationdevelopmenttosupportCS,andthen,selectsappropriateAPIandformulationmanufacturingrouteandmethodsbasedoncompound'spropertiestosupportnonclinicalsafetyandclinicalstudies.
NonclinicalSafetyEvaluationtoSupportFTIHandPoCTrialsCharlesY.
WANG,PhD,DABTDirectorandHeadofSafety,Assessment,GSKR&DShanghaiProductDevelopmentforEarlyStage:fromCandidateSelectiontoPOCClinicalStudyHengxuWEI,PhDDirectorofCMCRegulatory,GSKChina32Theme4TheBestPracticeforINDApplicationManagementSession401|Tuesday,25October13:30-15:006F,DoubleTreeGrandBallroom2INDMANAGEMENTANDCOMMUNICATIONWITHHEALTHAUTHORITIES---CHINAvs.
USSESSIONCHAIRWendyYAN,MD,MBASeniorVicePresident,HeadofRegulatoryAffairsBeiGene(Beijing)Co.
,Ltd.
Transparentandeffectivelycommunicationbetweensponsorsandhealthauthoritiesisoneofcrucialfactorsforsuccessfullynewdrugdevelopment.
Inthissession,speakersfromhealthauthorityandindustrywillpresenttheirthoughtandbestpracticeforcommunicationbetweensponsorandHealthauthorities.
INDOverviewandStrategyWendyYAN,MD,MBASeniorVicePresident,HeadofRegulatoryAffairsBeiGene(Beijing)Co.
,Ltd.
CommunicationsbetweenIndustryandCFDA/FDAduringDrugDevelopmentRuyiHE,MDChiefScientist,CDE/CFDALUYEPharmR&DintheExplorationofInternationalizationby505(b)(2)PathwayChunnaYOURegulatoryAffairsDirectorofLuyePharmaGroupLtd.
Session402|Tuesday,25October15:30-17:006F,DoubleTreeGrandBallroom2THEBESTPRACTICEFORINDAPPLICATIONPREPARATION---CHINAvs.
USSESSIONCHAIRDylanYAO,PhDChiefScientificOfficer,JOINNLaboratories(Beijing)Inc.
AnInvestigationalNewDrugApplication(IND)isarequestforFoodandDrugAdministration(FDA)authorizationtoadministeraninvestigationaldrugtohumans.
SuchauthorizationmustbesecuredpriortointerstateshipmentofthedrugcompoundintheUSandadministrationofanynewdrugthathasnotbeenapprovedbyFDA.
Fromaregulatoryperspective,althoughthereareanumberofrequirementsforanINDsubmission,includinginvestigator'sbrochure,clinicalprotocolandsoon,themostimportantinformationdeterminingifaninvestigationaldrugissafetobegiventohumansubjectsclinicallyaretwoparts:1.
SufficientCMCinformationtoensuretheproperidentity,strength,quality,andpurityoftheinvestigationaldrug.
TheamountofCMCinformationthatshouldbeprovidedwillvarywiththephaseoftheinvestigation,theproposeddurationoftheinvestigation,thedosageform,andtheamountofinformationotherwiseavailable.
TUESDAY,25OCTOBER|WEDNESDAY,26OCTOBER2.
Adequateinformationaboutthepharmacologicalandtoxicologicalstudiesoftheinvestigationaldruginvolvinglabanimalsorinvitrotestingtosupportthesponsor'sconclusionthatitisreasonablysafetoconducttheproposedclinicaltrial.
Thesponsorshouldincludeadiscussionoftherationalefortheinvestigationaldrug'sintendeddose,duration,schedule,androuteofadministrationintheproposedtrial.
Thisrationale,particularlyforphase1trials,isbestsupportedbyinvitroandavailableinvivoanimaldata,asdescribedintheguidanceforindustryContentandFormatofInvestigationalNewDrugApplications(INDs)forPhase1StudiesofDrugs.
AgreatdecisionmadebyChineseFDA(CFDA)recentlywasthatCFDAacceptsallregulatoryandtechniqueguidancefromtheWHO,FDAandICH,whichmadethedomesticpharmaindustrymucheasiertoconsider"dualregistration"oftheirnewdrugs.
Inthissession,Mr.
MingpingZhangwilltalkabout"TheBestPracticeorTipsofCMCDossierPreparationforINDsubmissioninChina",Ms.
JieCongwillshareherexperienceentitled"TheRiskmanagementandExperienceforChinaINDApplication",andaformerUSFDAseniorreviewerDr.
DylanYaowillpresentregulatoryrequiredinformationon"PreclinicalSafetyAssessmentforINDEnablingSubmissionintheUS",andaquestionandanswersessionwillbefollowedafterwards.
TheBestPracticeorTipsofCMCDossierPreparationforChinaINDMingpingZHANGPrincipalConsultant,PAREXELInternationalTheRiskManagement&ExperienceSharingforChinaINDApplicationJieCONGCEO,BeijingBioTellConsultingCo.
,LtdTheRegulatoryRequirementofPharmacologyandToxicologyforUSINDApplicationDylanYAO,PhDChiefScientificOfficer,JOINNLaboratories(Beijing)Inc.
33WEDNESDAY,26OCTOBERTheme5China-basedEarlytoMid-stageClinicalDevelopmentSession501|Wednesday,26October8:30-10:006F,DoubleTreeGrandBallroom2FROMFIRSTINHUMAN(FIH)TRIALTOCLINICALPROOFOFCONCEPT(POC)SESSIONCHAIRZaiqiWANG,PhDHeadofClinicalResearch,ExecutiveDirectorMSDChinaDevelopmentEarlydevelopmentcoversfromFIHuntilPOC.
ThekeyobjectivesforearlydevelopmentaretoachievePOCandprovidephaseappropriateclinicalpharmacologypackageforfuturedevelopment.
Inadditiontosafety,tolerabilityandPK/PD,exploringbiologicalactivityorhavinganearlyreadoutofefficacyusingbiomarkerandaddressingkeysafetyissuesareofsignificantvaluesforearlyclinicaldevelopment.
Inthissession,wewillhighlightthedeliverablesforearlydevelopmentandsharethepracticalandefficientdevelopmentplantoachievePOC.
Thiswillcover:Howtogeneratephaseappropriateclinicalpharmacologypackageinsupportearlydevelopmentneed,especially"lean-2-POC"BasedontherevisedICHE14inDec2015,howtoperformoptimalQTevaluationsasamajorsafetyissueintheearlyphaseclinicalprogramHowtoleveragebiomarkersforachievePOCsSharedlearningforcommonpitfallsforstudydesignandexecutionatinvestigativesiteincludingdataanalysisandreportdrafting.
Lean-2-POCEarlyDevelopmentApproachYueHUANG,PhD,EMBAHeadofClinicalPharmacologyChina,MerckSerono|GlobalEarlyDevelopmentOptimalQTEvaluationsinClinicalDrugDevelopmentCharlesXIE,MD,PhDDirector,EarlyClinicalDevelopment,BoehringerIngelheimChinaCommonIssuesandPitfallsatInvestigativeSitesJenniferHOU,MDCMO,eStartMedicalTechnologyLtd.
Session502|Wednesday,26October10:30-12:006F,DoubleTreeGrandBallroom2ADDRESSINGCHALLENGESFROMCFDANEWREQUIREMENTSONCLINICALTRIALCONDUCTANDDATAQUALITYSESSIONCHAIRDajunYANG,PhDChairmanandCEO,AscentagePharmaThissessionemphasizestheimportanceofpatientssafetyandqualitycontrolofclinicaltrialsfornovelmoleculesenteringtheclinicalstudiesforthefirsttime.
Threeexperiencedclinicaltrialexpertswillpresentclinicaltrialdatamonitoring,exposure-responserelationshipandPK/PDmodeling,andrecentguidancefromCDE/CFDAforclinicaltrials,aswellasBEstudiesinhealthvolunteersetc.
Participantswillhaveopportunitytohearthein-depthpresentationaswellasinteractivediscussionsabouttheearlyphaseclinicaltrialsespeciallyafterthenewregulationsandguidancessince2015.
EnsurePatientSafetyandStudyIntegritybyRisk-BasedMonitoringforMedicalDataSurveillanceChaucerLIN,MD,PhDSeniorMedicalDirector,HeadofTherapeuticAreas,JAPACandGlobalCNSTALead,PAREXELInternationalQualityManagementofHealthyVolunteersinEarlyClinicalandBioequivalenceResearchYiFANGDirectorofDrugClinicalTrialInstitution,PerkingUniversityPeople'sHospitalClinicalPK/PDModelingandDataQuality:ChallengeandStrategiesQingshanZHENGDirectorofClinicalResearchCenter,ShanghaiUniversityofTraditionalChineseMedicineTheme6BDandPartneringSession601|Wednesday,26October8:30-10:006F,DoubleTreeGrandBallroom1PARTNERINGEARLYTOACCELERATETRANSLATIONOFSCIENTIFICDISCOVERYTOCLINICALBENEFITSSESSIONCHAIRDarrenJI,MD,PhD,MBAVicePresident,GlobalHead,AsiaandEmergingMarketsPartneringF.
Hoffmann-LaRocheLTD.
Druginnovationisanexcitingyetalongjourney.
Fromthebuddingscientificpossibilitytotheclinicalsuccess,therearemanystepsrichinroadblocksandfavorabletraps.
Keystepsattheoperationlevelincludepreclinicalpharmacology,safetyassessment,PK/PD,CMC,clinicaltrialdesignandmanagement.
Atthestrategiclevel,itiscriticaltopositionfromdayonewhatafinalmarketeddrugwilllooklike,inclinicaldifferentiation,marketpositioning,andpricingetc.
Thekeytoasuccessfuldrugdeveloperistocollaborateearlywithexperiencedpartnersforsynergyandforenhancedprobabilityofsuccess.
34Theme7WhitepaperShowcaseSessionSession701|Tuesday,25October13:30-15:006F,DoubleTreeGrandBallroom3TargetandConceptValidationofAntibodyDrugsSESSIONCHAIRGuodongZHANGMarketingExecutiveDirectorWinconTheracellsBiotechnologiesCo.
,LtdConceptValidationofAntibodyDrugsonNon-humanPrimateGuodongZHANG,PhDSeniorScientist,WinconTheracellBiotechnologiesCo.
,Ltd.
TargetedAntibodyDrugScreeningandValidationbyinVIVOMolecularImagingJimWANG,PhDCTO,MitroBiotechCo.
,Ltd.
TopicTBDSpeakerTBDNanjingGalaxyBiopharmaceuticalCo.
,Ltd.
LunchMeetingWednesday,26October12:00-14:006F,DoubleTreeGrandBallroom1InvitationtoMaster'sBalconyXianpingLU,PhDCEO&ChiefScientificOfficer,ChipscreenBiosciences,Ltd.
JingsongWANG,MD,PhDAdvisortoAtlasVentureDajunYANG,PhDChairmanandCEO,AscentagePharmaKewenJIN,MDManagingPartner,SericaCapitalJimmyZHANG,PhD,MBAManagingDirector,Cross-borderInvestment,CLInvestmentGroupDarrenJI,MD,PhD,MBAVicePresident,GlobalHeadAsiaandEmergingMarketsPartneringF.
Hoffmann-LaRocheLTD.
WendyPAN,PhD,JDPartner,SidleyAustinLLPZaiqiWANG,PhDHeadofClinicalResearch,ExecutiveDirectorMSDChinaDevelopmentTUESDAY,25OCTOBERPanelDiscussionChrisLU,PhDVenturePartner,FrontlineBioVenturesYuwenLIUManagingPartner,BoheAngelFundNinglingWANGManagingPartnerofFinneganShanghaiOfficeSession602|Wednesday,26October10:30-12:006F,DoubleTreeGrandBallroom1CROSS-BORDERBUSINESSDEVELOPMENTSESSIONCHAIRJimmyZHANG,PhD,MBAManagingDirector,Cross-borderInvestment,CLInvestmentGroupCross-borderdealsareontherise:bothbyChinesecompaniesandinvestorsbuyingfromabroad,andbyforeigncompaniesbuyinginnovationsfromChinesecompanies.
Thispanelconsistsofbroadly-experienceddeal-makerswhoarebuyersandsellersfrombothChinaandabroad,investor,andattorney.
Theywillsharetheirexperienceanddiscussthecurrentcross-borderlandscapeandtrend,andthecaveatsduringthecross-bordertransactions.
Cross-borderBusinessDevelopmentLandscapeFengZHOU,PhDProduct&SolutionsSpecialist,IntellectualProperty&Science,ThomsonReutersPanelDiscussionSammyJIANG,DBA,MBAVPInternationalBusiness&Strategy,LuyePharmaGroupKewenJIN,MDManagingPartner,SericaCapitalMikeLIU,PhD,MBAExecutiveVicePresidentGlobalBusinessDevelopment,AlphamabWendyPAN,PhD,JDPartner,SidleyAustinLLPFengZHOU,PhDProduct&SolutionsSpecialist,IntellectualProperty&Science,ThomsonReuters35讲者索引SPEAKERINDEXLASTNAMEFIRSTNAMESESSION#CONGJie402CRIBBESScottPre-conferenceWorkshopCUIJasmine301DONGKelly301DONGXin202FANGYi502HERuyiKeynote&SpecialForum&401HOUJennifer501HUANGYue501JIDarren601JIQunsheng102JIANGSammy602JINKewen602LIHenry202LIMinSpecialForumLIQingSpecialForumLINChaucer502LIUMike602LIUYuwen601LUChris601LUXianpingOpeningPlenaryMEIHongkang101MUHuaSpecialForumPANWendy602PANGJunyongSpecialForumQIUJeanPre-conferenceWorkshopSCHLEYERAxelKeynoteSCHWEIZERLiangPre-conferenceWorkshop,101&102SHENHong201WANGCharles302LASTNAMEFIRSTNAMESESSION#WANGMinghan102WANGNingling601WANGZaiqi501WANGZuopeng301WEIHengxu302WENDanyiPre-conferenceWorkshopWUJim101WUYongqian102XIECharles501XIEYuli101YANWendy401YANGDajun502YAODylan402YOUChunna401YUHanryPre-conferenceWorkshopYUMichaelSpecialForumYUANJijunPre-conferenceWorkshopZENGQingbei201ZHANGHongjian202ZHANGJimmy602ZHANGMingping402ZHENGQingshan502ZHOUFeng602ZHUCarolOpeningPlenary40参展商介绍EXHIBITORS上海津石医药科技有限公司ShanghaiMedKeyMed-TechDevelopmentCo.
,Ltd上海津石医药科技有限公司2009年成立于上海,是中国最早的SMO之一,2011年被药明康德收购.
目前是中国规模最大,最专业的SMO.
拥有530余名员工,分布于国内59个城市.
拥有240项临床研究经验,Top20跨国制药中至少16家将津石医药作为重要的SMO供应商,与国内至少50家知名药企进行合作,与320多家医院建立长期合作关系,与超过70家主要医院建立优选SMO合作关系.
公司地址:上海马当路388号,SOHO复兴广场A座605室邮编:200025联系人:洪有源|电话:021-53061156|传真:021-53061209电子邮箱:Hong_youyuan@wuxiapptec.
com杭州泰格医药科技股份有限公司09HangzhouTigermedConsultingCo.
,Ltd杭州泰格医药科技股份有限公司(股票代码:300347)是一家专注于为新药研发提供临床试验全过程专业服务的合同研究组织(CRO).
我们致力为客户在降低研发风险、节约研发经费的同时,提供高质量的临床试验服务,从而推进产品市场化进程.
泰格医药总部位于杭州,下设33家子公司,在中国内地53个主要城市和香港、台湾、韩国、日本、马来西亚、新加坡、印度、澳大利亚、加拿大、美国等地设有全球化服务网点,拥有超过2000多人的国际化专业团队,为全球600多家客户成功开展了500余项临床试验服务.
泰格医药更因参与58余种国内创新药临床试验,而被誉为"创新型CRO".
公司地址:上海市中山西路999号华闻国际大厦1606室邮编:200051联系人:张东平|电话:021-32503700--8059传真:021-32503707电子邮箱:dongping.
zhang@tigermed.
netHangzhouTigermedConsultingCo.
,Ltd(stocksymbol:300347)isaleadingContractResearchOrganization(CRO)inChinadedicatedtoprovideprofessionalfullclinicaltrialservices.
Sinceinceptionin2004,Tigermedhasbeencommittedtoacceleratingmedicalproductdevelopmentwithcostsefficiencyandquality.
HeadquarteredinHangzhou,Tigermedoperates33subsidiaries,53officesacrossChinaand10overseasofficesinHongKong,Taiwan,USA,Canada,Korea,Australia,Japan,Malaysia,SingaporeandIndiawithover2000fulltimestaffs.
TigermedhassetupinternationalstandardSOPsandservicedmorethan600localandglobalclientsintheconductofover500clinicaltrials.
Tigermedisrecognizedas"TheInnovativeCRO"inChina,owningtoourinvolvementof58innovativedrugs.
FormoreinformationaboutTigermed,pleasevisitwww.
tigermed.
net北京易启医药科技有限公司06eStartMedicalTechnologyCo.
,Ltd.
易启医药科技有限公司(易启医药)是独具特色集学术与自身运营经验为一体并以早期临床试验为主的一站式服务合同研究组织(CRO),特别是创新药物首次人体试验及POC试验、仿制药一致性评价、生物等效试验、心脏毒性临床评价(IQT和TQT试验)等早期研究全产业链服务,同时包括项目注册和战略咨询、早期项目评估、方案设计和各种试验设计及报告撰写、项目管理和监查、项目稽查、数据管理、生物统计、电子数据采集(EDC).
公司地址:北京市海淀区首体南路20号6-1005邮编:100044联系人:郝娟|电话:13114800321|传真:010-88354800电子邮箱:Selina.
hao@estartmed.
net41参展商介绍EXHIBITORS药明康德制剂部PharmaceuticalDevelopmentServicesofWuXiAppTec药明康德制剂部(PharmaceuticalDevelopmentServices,PDS),成立于2007年,立足中国,面向世界,致力于服务全球的医药研发企业.
业务包括处方前开发、处方及工艺开发优化、制剂cGMP生产等.
在过去的九年时间里,不断拓展其业务范围与规模,先后三次通过欧盟的认证,通过美国FDA的检查,多次通过中国CFDA的现场核查,成功地为国外和国内的客户生产了一千多个批次的临床试验样品,供应一期、二期、三期临床试验.
两个商业化生产设施在建设中,预计2017年下半年投入使用,将通过MAH方式帮助客户进行商业化产品生产.
公司地址:上海外高桥富特中路288号中国(上海)自由贸易试验区邮编:200131联系人:郭劲松|电话:13764780301传真:+86(21)50461000电子邮箱:guo_jinsong@wuxiapptec.
com精鼎医药研究开发(上海)有限公司PAREXELInternational精鼎医药(PAREXELInternational)是世界顶尖的CRO公司.
我们为全球生物医药公司提供最全面的临床阶段研究开发服务,主要包括新药开发策略拟定与计划、国际临床试验规划执行及整合、临床试验监测、临床试验数据处理、临床研究统计分析、临床试验总结及统计报告、临床试验稽核、临床试验供应和物流、临床电子数据采集和医学信息管理系统、新药查验登记和国际临床试验相关法规咨询等.
公司地址:上海市银城中路488号太平金融大厦20F联系人:涂浩波|电话:51118973电子邮箱:Haobo.
tu@parexel.
com广西南宁灵康赛诺科生物科技有限公司03&04WinconTheraCellsBiotechnologiesCo.
,Ltd灵康赛诺科生物科技有限公司,专注于非人灵长类动物人类疾病模型与相关技术开发,依托核心专业团队的临床医学经验与临床前研究能力,利用中国华南地区丰富优质的灵长类实验动物资源,构建了独具特色的灵长类动物试验与开放式技术平台,籍此为全球制药、生物技术公司、科研院所医药健康产品研发和生物医学研究提供专业化、定制化的研究服务及解决方案.
灵康是中国首家通过AAALAC(国际实验动物管理评估及认证协会)国际资质认证的灵长类动物实验室,并在实验研究过程中严格遵循实验动物使用与关怀规范,保障动物的福利与动物实验的质量.
灵康始终不断提升自身的研发水平、新技术开发和平台服务能力,满足客户在产品开发及生物医学研究方面的高品质要求,通过持续的创新与合作逐步发展成为国际一流的生物高科技企业.
公司地址:广西南宁高新区发展大道3号邮编:530003联系人:AngelaHsu|电话:15607712132传真:+86-771-3215326电子邮箱:Angela.
hsu@winconlab.
com凯杰(苏州)转化医学研究有限公司05QIAGEN(Suzhou)TranslationalMedicineCo.
,Ltd.
凯杰(苏州)转化医学研究有限公司是一个为精准医疗提供完整解决方案的创新型公司.
凭借QIAGEN领先的仪器、试剂以及强大的技术团队,凯杰(苏州)能够为我们的合作伙伴提供从生物标志物的发现和检测方法开发、到新药临床试验病人分子检测和入组筛选,以及伴随诊断试剂盒开发和商业化的一站式服务.
我们希望与您携手,通过凯杰先进的核酸和蛋白诊断技术,运用我们的转化医学知识和经验,加速新药临床开发的节奏,为中国待解决的医疗需求提供个体化诊疗解决方案.
公司地址:苏州工业园区星湖街218号生物纳米园B5楼9楼邮编:215123联系人:胡满|电话:13916696851|传真:0512-86868619电子邮箱:moon.
hu@transmedchina.
com42成都先导药物开发有限公司HitGenLTDDNA编码化合物库设计及筛选技术是当前新药发现领域最前沿的技术之一,成都先导药物开发有限公司致力于打造全球最优质的具有自主知识产权的DNA编码化合物库,成为新药创制的新引擎.
目前,成都先导已经完成逾56亿库化合物的合成,成为全球规模化提供DNA编码化合物库筛选服务的三家公司之一,有望缩短新药发现周期2-3年,提高重大疾病疑难靶点的药物发现效率;同时,正在开展约30项新药开发项目,集中于慢性重大疾病如肿瘤、心血管、糖尿病、呼吸道疾病等领域.
公司地址:四川省成都市科园南路88号天府生命科技园B3栋7-10楼邮编610041联系人:薛海英|电话:028-85197385|传真:028-83310298电子邮箱:Hy.
xue@hitgen.
com武汉光谷生物城02WuhanBiolake光谷生物城位于武汉东湖国家自主创新示范区,是东湖高新区继光电子信息产业基地之后以"千亿产业"思路建设的第二个国家级产业基地,已建成生物创新园、生物医药园、生物农业园、医疗器械园、医学健康园五大园区,产业年均增长率保持在30%以上,产业收入突破千亿元,在全国108个生物园区中"大考"中,综合实力位列第二,其中基础竞争力和可持续发展竞争力全国第一.
公司地址:湖北省武汉市东湖高新区高新大道666号邮编:430070联系人:张小姐|电话:87001620|传真:87001612参展商介绍EXHIBITORS南通科瑞斯生物医药科技有限公司10中外合资企业科瑞斯总公司成立于2013年,是国内第一家能提供全面临床前心脏安全评估平台及离子通道新药研发的企业.
公司由多个在美国药企工作多年经验的海归博士所创立,50%的员工具有硕士以上的学历,现位于江苏省海门临江新区生物医药科创园.
公司实验室面积700m2,拥有多套先进的仪器和设备,能够提供从细胞到整体动物的不同水平的测试平台.
我们遵循美国药物非临床研究质量管理规范来管理实验平台进行临床前心脏安全评估及离子通道为靶点的新药研发.
为了开拓国内外市场,2016年8月,分公司创享生物在上海市浦东新区张江药谷成立.
公司地址:江苏省海门市临江新区科创园A5楼邮编:226133联系人张婷婷电话:13862865094电子邮箱:ttzhang@pharmacorelab.
com43铂金级支持方PlatinumLevelSupporter易启医药金牌级支持方GoldLevelSupporter药明康德制剂部展商学术交流研讨会WhitePaperShowcaseHost灵康赛诺科会议支持方PARTNERACKNOWLEDGEMENTSPAREXELInternational临床研究中的供应商选择、认证和管理研讨班12月8-9日|上海齐鲁万怡大酒店临床研究中的供应商选择,临床试验数据的可信度,与各种供应商的有效管理和沟通,是医药研发企业非常关注的,同时,也是合同研究组织(CRO),数据统计服务商(DM/STATServiceCompany),中心实验室(CLAB)等特别需要了解的.
研讨班将围绕临床试验中CRO及中心实验室供应商的选择原则,从药厂和供应商的角度共同讨论外包供应商选择的关注点、最佳合作策略及措施的确定、数据质量的监控措施等内容,就中国当前环境下申办方和供应商如何深化合作关系,给客户增加价值,及培养更符合客户需求的CRO进行讨论和总结,以期对行业发展带来更多帮助.
将采用授课、实例练习和讨论相结合的方式,共同学习提高.
本次会议邀请业界资深的临床运营负责人,研发采购负责人,数据管理和统计部负责人,CRO、SMO,CLAB的商务拓展负责人,进行课程设计.
使参会者可以了解外包供应商选择的关键点及基本原则;分析CRO/SMO招标的特点和要素;探讨项目执行过程中与CRO和中心实验室密切配合的最佳策略,有效的沟通和管理的经验;讨论本土CRO与国际CRO的特点;掌握CLAB选择的重点和数据的整合(dataintegration)的重要性,等等,并进行相关的案例分析和讨论.
在当今研究外包服务日趋热化的中国,知己知彼,才能百战不殆,甲乙双方的同台对话和讨论,会将商业运营管理中的机会和挑战进行更好的沟通,以待探讨共同提高和发展的战略和战术.
会议将围绕临床试验中CRO及中心实验室供应商的选择原则,从药厂和供应商的角度共同讨论外包供应商选择的关注点、最佳合作策略及措施的确定、数据质量的监控措施等内容,采用授课、实例练习和讨论相结合的方式,共同学习提高.
组织委员会主席张玥默沙东制药公司(中国),全球数据管理和标准亚太数据管理中心亚太区总监张艳QSquareSolution中心实验室亚太区负责人任科药明康德SMO津石医药总经理请联系王心蕾|邮箱:lily.
wang@DIAglobal.
org|电话:+86.
21.
605772402ndDIAChinaDrugDiscoveryInnovationConferenceOctober24-26DoubleTreebyHiltonHotelSuzhouOctober24|Monday|Day18:30-12:00Pre-conferenceWorkshop:NovelTechnologyApplicationsforDrugDiscovery|6thFloor,FunctionRoom413:30-17:00OpeningPlenary6thFloor,DoubleTreeGrandBallroomWelcomeAddressfromDIA,ProgramChairandSuzhouIndustrialPark2KeynoteSpeechesSpecialForum:CFDAReformandNationalNewDrugDevelopmentStrategy:theImpactonChinaDrugR&DandInnovation17:00-19:00WelcomeReceiption(AllAttendees)October25|Tuesday|Day2Theme1TargetSelectionandValidationTheme3INDEnablingStudies8:30-10:00Session1016thFloor,DoubleTreeGrandBallroom1TargetSelectionSession3016thFloor,DoubleTreeGrandBallroom2EfficacyandDMPKofDrugCandidate10:00-10:30TeaBreak10:30-12:00Session1026thFloor,DoubleTreeGrandBallroom1TargetValidationSession3026thFloor,DoubleTreeGrandBallroom2NonclinicalSafetyEvaluationandCMCtoSupportFTIHandPoCTrials12:00-13:30BuffetLunch5thFloorTheme2CompoundIdentification/OptimizationtoCompoundNominationTheme4:BestPracticesforINDApplicationManagementTheme7:WhitepaperShowcaseSession13:30-15:00Session2016thFloor,DoubleTreeGrandBallroom1MedicinalChemistryinLeadIdentification/OptimizationSession401|6thFloor,DoubleTreeGrandBallroom2INDManagementSystemandCommunicationwithHealthAuthorities–Chinavs.
USSession701|6thFloor,DoubleTreeGrandBallroom3TargetandConceptValidationofAntibodyDrugs15:00-15:30TeaBreak15:30-17:00Session2026thFloor,DoubleTreeGrandBallroom1DiseasePharmacology,ADMEandEarlySafetyEvaluationtoSupportLeadCompoundNominationSession4026thFloor,DoubleTreeGrandBallroom2TheBestPracticeforINDApplicationPreparation–Chinavs.
US17:00-19:00VIPReceiption(VIPandSpeakerOnly)October26|Wednesday|Day3Theme6BDandPartneringTheme5China-basedEarlytoMid-stageClinicalDevelopment8:30-10:00Session6016thFloor,DoubleTreeGrandBallroom1PartneringEarlytoAccelerateTranslationofScientificDiscoverytoClinicalBenefitsSession5016thFloor,DoubleTreeGrandBallroom2FromFirstinHuman(FIH)TrialtoClinicalProofofConcept(POC)10:00-10:30TeaBreak10:30-12:00Session6026thFloor,DoubleTreeGrandBallroom1Cross-borderBusinessDevelopmentSession5026thFloor,DoubleTreeGrandBallroom2AddressingChallengesfromCFDANewRequirementsonClinicalTrialConductandDataQuality12:00-14:00LunchMeeting6thFloor,DoubleTreeGrandBallroom1(InvitationtoMaster'sBalcony)14:30ConferenceClosing(ShuttleBustoHongqiaoAirport,SuzhouRailwayStation,SuzhouNorthRailwayStationandSuzhouIndustrialParkRailwayStation)DIAChinaHomePageWeiboWechatSubscriptionDIACHINAOCTOBER–DECEMBER2016PROGRAMSUnitA1618,TowerA,No.
3HaiDianAvenue,HaiDianDistrict,Beijing100080,ChinaTel:+861057042650|Fax:+861057042651Unit1590,OfficeBuilding,99XianXiaRoad,ChangNingDistrictShanghai200051,ChinaTel:+862160577239|Email:China@DIAglobal.
org|www.
DIAglobal.
orgDIAGlobalCenter:21DupontCircleNW,Suite300,Washington,DC20036Basel,Switzerland|Beijing/Shanghai,China|Horsham,PA,USA|Mumbai,India|Tokyo,Japan6thClinicalProjectManagementWorkshopIntermediatetoAdvancedNovember16-18|BeijingXinjiangPlazaNovember21-23|CourtyardbyMarriottShanghaiPudong2ndDIAChinaMedicalAffairsAdvancedWorkshopDecember1-3|CourtyardbyMarriottShanghaiPudongDIACHINAWechatSubscription亲们~快来扫一下吧~VendorSelection,QualificationandManagementWorkshopDecember8-9|CourtyardbyMarriottShanghaiPudongFDA/DIAGCPInspection&DataIntegrityWorkshopNovember7-8|BeijingXinjiangPlazaNovember10-11|ShanghaiInternationalConventionCenter2ndDIAChinaDrugDiscoveryInnovationConferenceOctober24-26|DoubleTreebyHiltonHotelSuzhou2017DIA中国本届年会将以"恪守临床价值导向,引领药物研发新趋势"为主题,以回归"临床价值"这一药物研发本质,夯实新药研发基础,促进高质量的新药开发,切实满足患者的需求.
当今全球药物研发呈现新的趋势,新技术的应用,基因诊断的引入,大数据和实时患者的监控,研发体系上下游的合作,跨领域的技术开发手段等,如何引入国际视角,进一步推动中国药物研发,希冀未来中国引领全球行业的发展,这将是一场新趋势的盛会.
去年以来,中国的法规变革巨大,保证药品的安全有效,遵循科学的各种规范,是CFDA药品科学监管的核心命题.
在仿制药一致性评价,鼓励与全球同步的新药开发上,非常值得各国监管机构,制药业,学术界的关注和共议.
2017我们期待巡礼中国药品监管改革与创新的新高地.
徐宁医学博士,工商管理硕士再鼎制药执行副总裁,临床研发及法规事务负责人薛斌中国食品药品国际交流中心主任2017中国国际药物信息大会暨第九届DIA中国年会2017年5月21-24日上海国际会议中心大会联席主席展览及广告机会大会指导委员会胡蓓博士,教授北京协和医院临床药理中心吕玉真罗氏(中国)投资有限公司亚太区法规部门负责人邵颖博士上海复星医药集团副总裁兼研发中心主任苏岭博士沈阳药科大学教授,药品监管科学研究所所长礼来亚洲基金风险合伙人王劲松医学博士AtlasVenture公司投资顾问朱立红工商管理硕士DIA中国区董事总经理中国北京市海淀区海淀大街3号A座16层1618室邮编:100080|电话:+861057042650中国上海市长宁区仙霞路99号尚嘉中心15楼1590室邮编:200051|电话:+862160577239传真:+861057042651|Email:China@DIAglobal.
org|www.
DIAglobal.
orgDIAGlobalCenter21DupontCircleNW,Suite300,Washington,DC20036Basel,Switzerland|Beijing/Shanghai,China|Horsham,PA,USA|Mumbai,India|Tokyo,Japan第九届DIA中国年会为公司提供多种展示机会.
包括:展览、会议支持、会刊广告、会议资料袋、欢迎招待会、VIP招待会、茶歇,以及会议中心内的广告机会,如悬挂条幅、扶梯广告、包柱广告等.
DIA中国年会展位销售工作由中国食品药品国际交流中心负责.
预定展位请联系:郑鹏先生|Email:zhengpeng@ccfdie.
org|电话:+8610822128666007成建英女士|Email:chengjy@ccfdie.
org|电话:+861082212866